Skip to content
Q1 '26Q4 '25Q3 '25Q2 '25Q1 '25
$205.99M+84.7%$111.54M-55.6%$251.08M+479%-$66.28M-263%-$18.25M+78.2%
$13.55M+0.3%$13.51M-2.2%$13.8M-1.0%$13.94M-3.2%$14.41M+1.7%
$70.15M-2.1%$71.63M-33.8%$108.21M-3.1%$111.68M+96.9%$56.71M-38.1%
$70.5M-56.9%$163.56M-49.7%$325.11M+109%$155.73M+229%-$120.31M-27.1%
$21.83M-6.3%$23.29M+91.8%$12.14M-15.0%$14.29M+59.3%$8.97M-1.4%
-$25.54M$0-100%$501.11M+454%-$141.38M-224%$113.77M+315%
$15.71M-$448.35M-966%$51.76M+12.3%$46.08M+48.7%
$53.61M-67.7%$166.01M-56.0%$376.94M+303%$93.61M+74.7%$53.6M
$48.67M-65.3%$140.26M-55.2%$312.97M+121%$141.44M+209%-$129.28M-24.6%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

How much cash does Alnylam Pharmaceuticals generate?
Alnylam Pharmaceuticals (ALNY) generated $714.9M in operating cash flow over the trailing twelve months.
What is Alnylam Pharmaceuticals's free cash flow?
After $71.6M of capital expenditures, Alnylam Pharmaceuticals's free cash flow was $643.3M over the trailing twelve months, up 931.4% year over year.
Where does Alnylam Pharmaceuticals's cash flow data come from?
Every line is extracted from Alnylam Pharmaceuticals's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.